NCT03168295View on ClinicalTrials.gov

PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

May 15, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin 10mg then Placebo Oral Tablet

SGLT2 inhibitor - Dapagliflozin then Placebo

DRUG

Placebo Oral Tablet then Dapagliflozin 10mg

Placebo then SGLT2 inhibitor - Dapagliflozin

Trial Locations (1)

78229

The University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT03168295 - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria | Biotech Hunter | Biotech Hunter